PathAI vs Butterfly Network

Butterfly Network has a disclosed valuation of $957M, while PathAI's valuation is not publicly available, making a direct size comparison difficult. Butterfly Network employs 500-1000 people.

PathAI has raised more in total funding at $490M, compared to Butterfly Network's $370M — a gap of $120M. Combined, the two companies have completed 8 known funding rounds.

Butterfly Network leads with an Awaira Score of 85/100, while PathAI sits at 62/100. That 23-point gap reflects real differences in funding, scale, and traction — it's not a vanity metric.

PathAI was founded by Andy Beck in 2016. Butterfly Network was founded by John Martin in 2011. Visit each company's profile on Awaira for a full founder biography.

PathAI: PathAI is an AI healthcare company founded in 2016 that develops digital pathology solutions and AI-powered diagnostic tools for pathology labs and healthcare institutions. The company specializes in machine learning algorithms designed to assist pathologists in analyzing tissue samples and identifying diseases, particularly cancer. PathAI's core technology platform applies deep learning and computer vision to process histopathology images, enhancing diagnostic accuracy and workflow efficiency. The company's primary offering includes software that integrates with existing laboratory information systems, enabling pathologists to use AI-assisted analysis for specimen evaluation. PathAI has developed partnerships with major healthcare systems and diagnostic laboratories, demonstrating clinical utility in oncology and other pathology specialties. The platform addresses critical challenges in pathology including diagnostic consistency, workload management, and access to specialized expertise in underserved regions. PathAI has raised $255 million in total funding as of its Series C stage, with valuation not disclosed. The company operates in the competitive digital pathology and AI diagnostics space, alongside competitors offering similar computational pathology solutions. The digital pathology market is experiencing significant growth driven by increasing diagnostic demands, laboratory automation trends, and regulatory acceptance of AI-assisted tools. PathAI's trajectory reflects broader momentum in AI-enabled healthcare diagnostics and precision medicine applications. PathAI combines deep learning with pathology workflows to create clinically integrated AI tools that assist rather than replace human pathologists. Butterfly Network: Butterfly Network produces the Butterfly iQ, a handheld ultrasound device powered by a proprietary semiconductor chip that replaces traditional piezoelectric transducer arrays with a single silicon chip capable of whole-body imaging. The AI software layer provides real-time image interpretation guidance, enabling clinicians with limited ultrasound training to perform diagnostic scans at the bedside.\n\nThe company is publicly traded on the NYSE under the ticker BFLY and raised over 700 million USD prior to and through its public listing. Butterfly has deployed devices across hospitals, emergency rooms, and point-of-care settings in over 50 countries, with particular penetration in resource-limited healthcare settings where traditional ultrasound equipment is prohibitively expensive or unavailable.\n\nPortable AI-assisted diagnostic imaging represents a structural shift in how and where medical imaging is performed. Butterfly Network has created a defensible position through its proprietary chip architecture, which competitors cannot easily replicate, and through its growing library of AI-assisted clinical guidance tools. The transition from hospital-based imaging to point-of-care diagnostics powered by AI guidance is a multi-decade trend that positions Butterfly at the center of a fundamental change in diagnostic medicine. Butterfly Network operates in the AI Healthcare sector and is headquartered in United States. Founded in 2011 by John Martin, Butterfly Network has raised $370M in total funding, achieving a valuation of $957M as of its latest round. The company's funding journey includes a Seed of $11.1M in 2011, a Series A of $29.6M in 2012, a Series B of $66.6M in 2014, a Series C of $114.7M in 2015, a Series D of $148M in 2016. With approximately 500-1000 employees, Butterfly Network has established itself as a Public-stage player in the AI Healthcare market. The company holds an Awaira Score of 85/100, reflecting its strong position across valuation, funding trajectory, team scale, and market influence. Butterfly Network competes in a rapidly evolving segment alongside other AI Healthcare companies. Based in United States, Butterfly Network is part of a growing international AI ecosystem attracting talent and investment. The AI Healthcare space has attracted significant investment in recent years, with companies racing to capture enterprise and consumer demand for AI-powered solutions.

Butterfly Network got there first, launching in 2011 — that's 5 years of extra runway. PathAI didn't arrive until 2016. In AI, that kind of head start means more training data, deeper customer relationships, and a bigger talent moat.

PathAI has about 300 employees; Butterfly Network has about 500-1000. A bigger team usually means more revenue or heavier VC backing, but in AI, small teams can build at massive scale.

Yes — they're direct rivals. Both PathAI and Butterfly Network compete in AI Healthcare, targeting many of the same buyers. If you're evaluating one, you should be looking at the other.